Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Intangibles (2016 - 2025)

Celldex Therapeutics has reported Intangibles over the past 16 years, most recently at $27.2 million for Q4 2025.

  • Quarterly results put Intangibles at $27.2 million for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $27.2 million (changed 0.0% YoY), and the annual figure for FY2025 was $27.2 million, changed 0.0%.
  • Intangibles for Q4 2025 was $27.2 million at Celldex Therapeutics, roughly flat from $27.2 million in the prior quarter.
  • Over the last five years, Intangibles for CLDX hit a ceiling of $30.7 million in Q1 2021 and a floor of $27.2 million in Q3 2021.
  • Median Intangibles over the past 5 years was $27.2 million (2022), compared with a mean of $27.5 million.
  • Biggest five-year swings in Intangibles: tumbled 39.85% in 2021 and later rose 0.04% in 2022.
  • Celldex Therapeutics' Intangibles stood at $27.2 million in 2021, then changed by 0.0% to $27.2 million in 2022, then changed by 0.0% to $27.2 million in 2023, then changed by 0.0% to $27.2 million in 2024, then changed by 0.0% to $27.2 million in 2025.
  • The last three reported values for Intangibles were $27.2 million (Q4 2025), $27.2 million (Q3 2025), and $27.2 million (Q2 2025) per Business Quant data.